Weight-Loss Segment Future Uncertain With PPA Actions, Ephedra Questions
This article was originally published in The Tan Sheet
Executive Summary
FDA actions discouraging the use of phenylpropanolamine-containing products will further accelerate the recent shift away from the OTC appetite suppressant ingredient toward ephedra supplements.
You may also be interested in...
Glaxo Claims OTC Switch Dominance With An Eye Toward Xenical In 2006
GlaxoSmithKline believes an OTC switch of the prescription weight-loss drug Xenical (orlistat) could have the same success as its nonprescription nicotine replacement therapy offerings
Business In Brief
Pfizer: Consumer Healthcare sales of $741 mil., up 14%, in the second quarter, were driven by the continued strong performance of Listerine mouthwash and uptake of Listerine PocketPaks in international markets. The rollout of FreshBurst Listerine line extensions and the weaker dollar also helped edge up revenues. Sales of PocketPaks in the U.S. slowed and the firm's Benadryl and Sudafed line were hurt by the presence of OTC Claritin on the market, Pfizer notes...
Chattem settles PPA suit
Consumer products firm will pay $3 mil. settlement plus $500,000 "for certain fees and expenses" to Jennifer Villarreal, who suffered a hemorrhagic stroke "after allegedly ingesting Dexatrim containing PPA," Chattem says May 7. Case was scheduled for trial on May 19 in Brazoria County, Tex. district court. Chattem "will be fully released from any further liability in the case" and the settlement "will be fully funded" by firm's product liability insurance coverage and thus should not impact results of operations, Chattem says. Firm stopped formulating Dexatrim with PPA after researchers found a link to hemorrhagic stroke and FDA issued a voluntary recall (1"The Tan Sheet" Nov. 13, 2000, p. 6). Chattem notes there are no other trials currently scheduled involving Dexatrim...